Cassava Sciences Files 8-K
Ticker: FLNA · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
TL;DR
Cassava Sciences filed an 8-K on Nov 25, 2024. No major news yet.
AI Summary
Cassava Sciences, Inc. filed an 8-K on November 25, 2024, reporting other events and financial statements. The company, previously known as Pain Therapeutics Inc., is incorporated in Delaware and headquartered in Austin, Texas. This filing does not appear to contain specific transactional details or financial figures beyond the reporting date.
Why It Matters
This 8-K filing indicates Cassava Sciences is providing updates to the SEC, which could relate to ongoing business activities or financial reporting requirements.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without specific material disclosures that would immediately impact risk.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- Pain Therapeutics Inc. (company) — Former company name
- November 25, 2024 (date) — Date of earliest event reported
- Austin, Texas (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text of the 8-K filing does not detail the specific 'Other Events' being reported, only that this item is included.
What is the significance of filing 'Financial Statements and Exhibits' on this date?
Filing 'Financial Statements and Exhibits' indicates that Cassava Sciences is providing required financial information or exhibits to the SEC, though the content of these is not specified in the provided excerpt.
When was Cassava Sciences, Inc. previously known as?
Cassava Sciences, Inc. was formerly known as Pain Therapeutics Inc., with a date of name change on March 9, 2000.
Where are Cassava Sciences, Inc.'s principal executive offices located?
The principal executive offices of Cassava Sciences, Inc. are located at 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
What is the Commission File Number for Cassava Sciences, Inc.?
The Commission File Number for Cassava Sciences, Inc. is 001-41905.
Filing Stats: 485 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-11-25 07:35:10
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- f8k_112524.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 32KB
- 0001171843-24-006545.txt ( ) — 247KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_112524_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On November 25, 2024, Cassava Sciences, Inc. (the "Company") issued a press release announcing that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The press release also announced the Company's decision to discontinue its Phase 3 ReFocus-ALZ study and its open label extension study. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release issued by Cassava Sciences, Inc., dated November 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cassava Sciences, Inc. a Delaware corporation Date: November 25, 2024 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer